找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Cholestatic Liver Disease; Keith D. Lindor,Jayant A. Talwalkar Book 20081st edition Humana Press 2008 autoimmune hepatitis.biopsy.liver tr

[复制链接]
楼主: Exacting
发表于 2025-3-25 06:32:09 | 显示全部楼层
https://doi.org/10.1007/978-3-663-02723-2pensated liver disease may eventually develop. Ursodeoxycholic acid is the only recommended treatment and may improve survival in selected patients. Prognostic models help predict natural history of the disease. Liver transplantation is the only definitive therapy once end-stage liver disease occurs.
发表于 2025-3-25 09:39:26 | 显示全部楼层
发表于 2025-3-25 15:39:20 | 显示全部楼层
发表于 2025-3-25 19:10:39 | 显示全部楼层
2197-7399 seful for both novice and practitioners alike. Among the topics discussed in this volume are PBC, PSC, overlap syndrome with autoimmune hepatits, sarcoid, lymphoma, cystic fibrosis, rheumatologic disease, and o978-1-59745-118-5Series ISSN 2197-7399 Series E-ISSN 2197-7704
发表于 2025-3-25 20:57:48 | 显示全部楼层
发表于 2025-3-26 02:51:43 | 显示全部楼层
Schriften zur Datenverarbeitungessive disease which slowly advances over time and may shorten life expectancy. The most severe problem that can develop is bile duct cancer. No effective medical therapy is yet available for the underlying disease. Ursodeoxycholic acid is perhaps the best studied, but data from long-term clinical t
发表于 2025-3-26 07:33:26 | 显示全部楼层
发表于 2025-3-26 09:27:41 | 显示全部楼层
Primary Sclerosing Cholangitis,essive disease which slowly advances over time and may shorten life expectancy. The most severe problem that can develop is bile duct cancer. No effective medical therapy is yet available for the underlying disease. Ursodeoxycholic acid is perhaps the best studied, but data from long-term clinical t
发表于 2025-3-26 13:54:21 | 显示全部楼层
发表于 2025-3-26 20:13:28 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 吾爱论文网 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
QQ|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-8-25 22:04
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表